Skip to main content

Table 3 Median (IQR) serum values of Klotho, FGF19 and FGF21 in relation to the occurrence of metabolic syndrome and its components as well as insulin resistance and impaired glucose tolerance

From: Klotho and fibroblast growth factors 19 and 21 serum concentrations in children and adolescents with normal body weight and obesity and their associations with metabolic parameters

 Condition presentCondition absentP value
Klotho
 Central obesity (N = 116)156.4 (89.6 to 350.9)118.5 (48.4 to 177.5)0.0275
 Low HDL (N = 32)156.4 (92.4 to 266.7)134.4 (75.5 to 335.8)0.8202
 High TG (N = 23)134.2 (90.7 to 321.1)140.3 (75.5 to 313.0)0.5620
 Hypertension (N = 63)157.5 (90.2 to 321.1)136.0 (63.9 to 313.0)0.1975
 Metabolic syndrome (N = 18)172.7 (123.0 to 321.1)135.0 (75.1 to 305.0)0.2050
 Impaired glucose tolerance (N = 8)159.6 (131.8 to 208.3)136.4 (75.5 to 323.1)0.4948
 Insulin resistance (N = 48)185.3 (102.1 to 398.2)132.6 (63.9 to 275.6)0.0283
FGF19
 Central obesity (N = 116)160.6 (92.2 to 260.2)229.4 (119.5 to 345.0)0.0264
 Low HDL (N = 32)147.6 (79.4 to 257.8)194.2 (112.4 to 289.2)0.1727
 High TG (N = 23)124.3 (79.3 to 213.8)184.9 (112.4 to 297.8)0.0136
 Hypertension (N = 63)145.7 (93.3 to 244.5)197.7 (101.1 to 299.7)0.1085
 Metabolic syndrome (N = 18)133.0 (62.2 to 171.2)186.5 (109.2 to 284.7)0.0509
 Impaired glucose tolerance (N = 8)86.9 (65.4 to 149.4)183.8 (106.0 to 289.2)0.0416
 Insulin resistance (N = 48)143.0 (81.5 to 229.3)195.6 (118.2 to 297.8)0.0233
FGF21
 Central obesity (N = 116)93.0 (48.8 to 199.5)70.1 (31.5 to 108.6)0.0193
 Low HDL (N = 32)100.3 (48.8 to 165.1)84.7 (42.1 to 161.0)0.5064
 High TG (N = 23)124.6 (78.6 to 363.5)81.1 (39.5 to 151.3)0.0035
 Hypertension (N = 63)124.6 (61.3 to 260.3)75.2 (39.4 to 115.3)0.0004
 Metabolic syndrome (N = 18)136.2 (86.5 to 239.9)82.6 (41.8 to 152.4)0.0286
 Impaired glucose tolerance (N = 8)107.2 (66.2 to 216.8)86.4 (42.2 to 161.0)0.4767
 Insulin resistance (N = 48)91.9 (44.5 to 159.0)82.6 (42.2 to 161.0)0.6314
  1. Numbers in first column represent the number of patients with a given clinical condition. The remainder of the group (174-N) were free from these ailments
  2. MS-metabolic syndrome, FGF19 – fibroblast growth factor 19, FGF21 - fibroblast growth factor 21
  3. Significant differences between patients with or without each condition (in columns) were bolded